Patent Dispute Ends: Genentech and Abbott Laboratories...
From Times Staff and Wire Service Reports
Patent Dispute Ends: Genentech and Abbott Laboratories have agreed to drop their counter claims over two Abbott patents on a substance known as plasminogen activator. Genentech, of South San Francisco, said the out-of-court settlement means that it can continue unrestricted sales of its tissue plasminogen activator, a drug for treatment of heart attack victims.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
